Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RYTM
RHYTHM PHARMACEUTICALS, INC.
NASDAQ
$102.74
▼ DOWN 2.05% (-2.15)

KEY STATISTICS

Market Cap$6.99 B
52w High$122.20
52w Low$74.50
Dividend Yield—
Frequency—
P/E-33.04
Volume466.90K
Shares Out.68.59M

COMPANY

LEADERSHIP

David Meeker
CHIEF EXECUTIVE
David Meeker

COMPENSATION 2026

Salary$807,692
Stock Awards$8,274,785
Incentive Plan Pay$759,488
All Other Comp.$14,000
Total$17,544,525

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 9, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
414

PRICE TARGET

Target High$160.00
Target Low$120.00
Target Median$143.00
Target Consensus$143.71

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$83.94M
NOV
3
TUE

PRICE

$102.74 ▼ DOWN 2.05% (−$2.15)
$102$103$1049:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM102.74

About Rhythm Pharmaceuticals, Inc.

https://www.rhythmtx.com ↗

Rhythm Pharmaceuticals, founded in 2008 and based in Boston, develops therapies like IMCIVREE for rare genetic obesity disorders, including POMC, LEPR deficiencies, and syndromes like Bardet-Biedl.

INDUSTRY

Biotechnology

A PRODUCT RHYTHM PHARMACEUTICALS, INC. IS KNOWN FOR

IMCIVREE® (setmelanotide)
IMCIVREE® (setmelanotide)

IMCIVREE® is a precision medicine targeting severe obesity and hyperphagia caused by rare MC4R pathway genetic defects, serving as the company's lead product for neuroendocrine rare disease therapies.

COMPETITORS

COMPETITOR
LLY COMPARE
NVO COMPARE
REGN COMPARE
VKTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$51.3M $57.25M ▲$60.11M ▲$71.25M ▲
License-$5.01M $10.03M ▲— —

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
NonUS$13.08M $18.27M ▲$23.22M ▲$20.27M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
158
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.01% · 2.2M
IWM
0.19% · 1.4M
XBI
1.13% · 1.2M
SCHA
0.14% · 296.9K
JGRO
0.21% · 199.5K
FESM
0.23% · 142.3K
TMSL
0.19% · 53.4K
XRSU.L
0.19% · 49.5K
LABU
0.74% · 41.2K
FNY
0.61% · 33.1K
RSSL
0.19% · 26.5K
GSC
0.76% · 20.0K
JHMM
0.03% · 19.6K
MEDI
3.98% · 16.7K
BBP
1.45% · 16.6K
FSML
1.11% · 15.8K
FSCC
0.37% · 12.7K
PRFZ
0.05% · 12.2K
OZEM
1.49% · 8.9K
WELP.L
4.67% · 6.8K
PTL
0.04% · 3.4K
TILT
0.01% · 3.1K
BIB
0.24% · 2.5K
BKSE
0.24% · 2.0K
PQ
PQSG
0.18% · 1.3K
ETLZ.DE
0.04% · 943

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
409
TOP 12 OF 409 · RANKED BY POSITION SIZE
Perceptive Advisors LLC
419.1M sh · $288.39M
Blackrock Inc.
6.7M sh · $276.82M
Ra Capital Management, L.P.
6.7M sh · $740.22M
Blackrock, Inc.
6.3M sh · $636.46M
Vanguard Group Inc
6.2M sh · $664.82M
Baker Bros. Advisors LP
5.6M sh · $622.27M
Primecap Management Co/Ca/
4.3M sh · $430.51M
Nea Management Company, LLC
2.9M sh · $311.48M
Jpmorgan Chase & Co
2.7M sh · $292.18M
State Street Corp
2.6M sh · $285.73M
Price T Rowe Associates Inc /Md/
2.6M sh · $284.92M
Westfield Capital Management Co LP
2.2M sh · $245.22M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Smith Hunter C
Purchase · 57.2K shares
2026-08-31
★
OFFICER: CHIEF FINANCIAL OFFICER
Smith Hunter C
Sale · 11.5K shares
2026-08-31
★
OFFICER: CHIEF FINANCIAL OFFICER
Smith Hunter C
Sale · 57.2K shares
2026-08-31
★
OFFICER: CHIEF FINANCIAL OFFICER
Smith Hunter C
Sale · 23.1K shares
2026-08-31

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OVERWEIGHT 3
MARKET OUTPERFORM 2
OUTPERFORM 1
13 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Citigroup BUY Citizens MARKET OUTPERFORM RBC Capital OUTPERFORM Canaccord Genuity BUY Wells Fargo OVERWEIGHT HC Wainwright & Co. BUY B of A Securities BUY

SECTORS PEERS

PEERPRICE
RVMD$209.08COMPARE
PTGX$145.80COMPARE
KNSA$78.37COMPARE
RLAY$19.06COMPARE
QURE$44.10COMPARE
VRDN$22.85COMPARE
STOK$29.66COMPARE
SNDX$20.63COMPARE